Haemonetics (NYSE: HAE) reported Q1 EPS of $1.02, $0.01 better than the analyst estimate of $1.01. Revenue for the quarter came in at $336.17 million versus the consensus estimate of $335.05 million.

GUIDANCE:

Haemonetics sees FY2025 EPS of $4.45-$4.75, versus the consensus of $4.60.

For earnings history and earnings-related data on Haemonetics (HAE) click here.